Remove 2019 Remove Chronic Condition Remove Clinic Remove Healthcare Professional
article thumbnail

Psychedelics – reasons for caution: Stacy Fischer, Brian Anderson, Theora Cimino

GeriPal

FDA is considering approval, shifting away from Schedule I restrictions, paving the way for use in clinical practice. Potential use in palliative care , chronic pain , and for mood disorders is tantalizing. In our prior podcast with Ira Byock on psychedelics in 2019 we talked primarily about the potential of psychedelics.